Imugene Overview
- Year Founded
-
1986
- Status
-
Public
- Employees
-
5
- Stock Symbol
-
IMU
- Investments
-
5
- Share Price
-
$0.02
- (As of Friday Closing)
Imugene General Information
Description
Imugene Ltd is an Australian-headquartered clinical stage cell therapy company developing an Allogeneic CAR T for blood cancers. Its lead asset is an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. The lead asset, azer-cel, is an allogeneic CAR T cell therapy targeting CD19 positive cancer cells. Autologous CAR T therapies, which use the patient's own modified T cells, azer-cel uses donor-derived T cells that are genetically engineered to attack cancer cells. The group has identified one reportable segment, being the research and development of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours.
Contact Information
Website
www.imugene.comCorporate Office
- 4-6 Bligh Street, Level 12
- Suite 12.01
- Sydney, New South Wales 2000
- Australia
Corporate Office
- 4-6 Bligh Street, Level 12
- Suite 12.01
- Sydney, New South Wales 2000
- Australia
Imugene Timeline
Imugene Stock Performance
As of 13-Nov-2026, Imugene’s stock price is $0.02. Its current market cap is $13.6M with 554M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.02 | $0.02 | $0.02 - $0.27 | $13.6M | 554M | 2.71M |
Imugene Financials Summary
As of 30-Sep-2026, Imugene has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | 18,920 | 26,579 | 49,954 | 190,884 |
| EBITDA | (68,251) | (45,179) | (98,582) | |
| Net Income | (71,358) | (44,658) | (98,091) | |
| Total Assets | 15,850 | 54,599 | 101,194 | |
| Total Debt | 4,335 | 6,957 | 0 |
Imugene Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Imugene Comparisons
Industry
Financing
Details
Imugene Competitors (2)
One of Imugene’s 2 competitors is Argos Therapeutics, a Venture Capital-Backed company based in Durham, NC.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Argos Therapeutics | Venture Capital-Backed | Durham, NC | ||||
| Amphivena Therapeutics | Venture Capital-Backed | South San Francisco, CA |
Imugene Patents
Imugene Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12698512-B2 | Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers | Active | 06-Nov-2023 | ||
| US-20250146017-A1 | Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers | Active | 06-Nov-2023 | ||
| US-20260317787-A1 | Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers | Pending | 06-Nov-2023 | ||
| WO-2025101672-A1 | Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers | Inactive | 06-Nov-2023 | ||
| AU-2018904373-A0 | Methods of treating proliferative disorders | Inactive | 16-Nov-2018 |
Imugene Signals
Imugene Investments & Acquisitions (5)
Imugene’s most recent deal was a Merger/Acquisition with Vaxinia for . The deal was made on 18-Nov-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Vaxinia | 18-Nov-2019 | Merger/Acquisition | Drug Discovery | ||
| City of Hope (CF33 oncolytic virus) | 15-Jul-2019 | Corporate Asset Purchase | Buildings and Property | ||
| Baker Heart and Diabetes Institute (Immuno-Oncology Technology) | 13-Dec-2016 | Corporate Asset Purchase | Buildings and Property | ||
| Biolife Science | 23-Oct-2013 | Merger/Acquisition | Drug Discovery | ||
| Lingual Consegna | 31-Jul-2012 | Merger/Acquisition | Drug Delivery |
Imugene ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
36.43 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Imugene Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Imugene (Cell Therapy Manufacturing Facility in North Carolina) | NC |
Imugene FAQs
-
When was Imugene founded?
Imugene was founded in 1986.
-
Where is Imugene headquartered?
Imugene is headquartered in Sydney, Australia.
-
What is the size of Imugene?
Imugene has 5 total employees.
-
What industry is Imugene in?
Imugene’s primary industry is Drug Discovery.
-
Is Imugene a private or public company?
Imugene is a Public company.
-
What is Imugene’s stock symbol?
The ticker symbol for Imugene is IMU.
-
What is the current stock price of Imugene?
As of 13-Nov-2026 the stock price of Imugene is $0.02.
-
What is the current market cap of Imugene?
The current market capitalization of Imugene is $13.6M.
-
Who are Imugene’s competitors?
Argos Therapeutics and Amphivena Therapeutics are competitors of Imugene.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process